Cascade testing in familial hypercholesterolaemia: How should family members be contacted?

European Journal of Human Genetics

Volumn 13, Issue 4, 2005, Pages 401-408

  Newson, Ainsley J ^a,b   Humphries, Steve E ^b,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b London IDEAS Genetics Knowledge Park   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Autonomy; Cascade genetic screening; Cascade testing; Confidentiality; Ethics; Familial hypercholesterolaemia; Genetics; Guidelines

Indexed keywords

ACCURACY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONFIDENTIALITY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HEALTH; GENETIC RISK; GENETIC SCREENING; HEALTH PROGRAM; HUMAN; HUMAN RIGHTS; INTERPERSONAL COMMUNICATION; LIFE EXPECTANCY; MEDICAL ETHICS; MEDICAL INFORMATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RELATIVE; RISK ASSESSMENT; SOCIAL ISOLATION;

GENETICS AND REPRODUCTION;

CONFIDENTIALITY; ETHICS, MEDICAL; FAMILY; GENETIC SCREENING; GENETIC TECHNIQUES; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PATIENT ADVOCACY; TRUTH DISCLOSURE;

EID: 17144387029     PISSN: 10184813     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ejhg.5201360     Document Type: Article

References (37)

1. Goldstein JL, Brown MS: Familial hypercholesterolaemia; in Scriver CR, Beudet AL, Sly WS et al (eds): The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 2000, pp 1215-1245.
2. Stone NJ, Levy RI, Fredrickson DS, Verter J: Coronary artery disease in 116 kindred with familial type II hyperproteinemia. Circulation 1974; 49: 476-488.
3. Slack J: Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 27: 1380-1382.
4. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE: Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000; 321: 148.
5. Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142: 105-112.
6. Thompson GR, Maher VM, Matthews S et al: Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345: 811-816.
7. Heath KE, Humphries SE, Middleton-Price H, Boxer M: A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001; 9: 244-252.
8. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA: A cost-effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 2002; 324: 1303.
9. Leren TP: Cascade genetic screening for familial hypercholesterolaemia (review). Clin Genet 2004; 66: 483-487.
10. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ: Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001; 357: 165-168.
11. van Maarle MC, Stouthard ME, Bonsel GJ: Quality of life in a family based genetic cascade screening programme for familial hypercholesterolaemia: a longitudinal study among participants (letter). J Med Genet 2003; 40: e3.
12. Secretary of State for Health: Our Inheritance, Our Future: Realising the Potential of Genetics in the NHS 2003, http://www.dh.gov.uk/assetRoot/04/01/92/39/04019239.pdf (1 June 2004) at [3.10]-[3.12].
13. Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Ayme S: Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet 2003; 11: S123-S142.
14. Andersen LK, Jensen HK, Juul S, Faergeman O: Patients' attitudes toward detection of heterozygous familial hypercholesterolemia. Arch Intern Med 1997; 157: 553-560.
15. Marteau T, Senior V, Humphries S et al: Psychological impact of genetic testing for familial hypercholesterolaemia within a previously aware population: a randomized controlled trial. Am J Med Genet 2004; 128A: 285-293.
16. Chandros Hull S, Glanz K, Steffen A, Wilfond BS: Recruitment approaches for family studies: attitudes of index patients and their relatives. IRB: Ethics Hum Res 2004; 26: 12-18.
17. Worral B, Chen D, Meschia J: Ethical and methodological issues in pedigree stroke research. Stroke 2001; 32: 1242-1249.
18. Tonstad S, Vollebaek LE, Ose L: Screening for familial hypercholesterolaemia in relatives (letter). Lancet 1995; 346 1438.
19. Laurie G: Obligations arising from genetic information - negligence and the protection of familial interests. Child Family Law Quart 1999; 11: 109-124.
20. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN: Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 2000; 321 1497-1500.
21. van Maarle MC, Stouthard ME, Marang-van de Mheen PJ, Klazinga NS, Bonsel GJ: How disturbing is it to be approached for a genetic cascade screening programme for familial hypercholesterolaemia? Psychological impact and screenees' views. Community Genet 2002; 4: 244-252.
22. Ose L, Vollebaek LE, Tonstad S: Attitude to genetic screening for familial hypercholesterolemia [Norwegian]. Tidsskr Nor Laegeforen 1998; 118: 1578-1581.
23. Morris JK, Law MR, Wald NJ: Is cascade testing a sensible method of screening a population for autosomal recessive disorders? Am J Med Genet 2004; 128A: 271-275.
24. Wilcke JT, Seersholm N, Kok-Jensen A, Dirksen A: Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives. Am J Hum Genet 1999; 65: 902-909.
25. Wilcke JT, Seersholm N, Kok-Jensen A, Dirksen A: Attitudes toward an unsolicited approach in relation to status of genetic disease: exemplified by alpha(1)-antitrypsin deficiency. Am J Med Genet 2000; 94: 207-213.
26. Wright C, Kerzin-Storrar L, Williamson PR et al: Comparison of genetic services with and without genetic registers: knowledge, adjustment, and attitudes about genetic counselling among probands referred to three genetic clinics. J Med Genet 2002; 39 e84.
27. Kerzin-Storrar L, Wright C, Williamson PR et al: Comparison of genetic services with and without genetic registers: access and attitudes to genetic counselling services among relatives of genetic clinic patients. J Med Genet 2002; 39: e85.
28. Super M, Schwarz MJ, Malone G, Roberts T, Haworth A, Dermody G: Active cascade testing for carriers of cystic fibrosis gene. BMJ 1994; 308: 1462-1467.
29. Chadwick R, Levitt M, Shickle D (eds): The Right to Know and the Right Not to Know. Aldershot, Avebury, 1997.
30. Hodge JG: Ethical issues concerning genetic testing and screening in public health. Am J Med Genet 2004; 125C: 66-70.
31. Neil HA, Hammond T, Mant D, Humphries SE: Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328: 500-501.
32. Arar NH, Plaetke R, Arar MY, Kasinath BS, Abboud HE: Incorporating the contextual assessment approach to regimens used in genetic family studies. Genet Med 2002; 4: 451-463.
33. Sermijn E, Goelen G, Teugels E et al: The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation (letter). J Med Genet 2004; 41: e23.
34. Gordon C, Walpole I, Zubrick SR, Bower C: Population screening for cystic fibrosis: knowledge and emotional consequences 18 months later. Am J Med Genet 2003; 120A: 199-208.
35. Human Genetics Commission: Inside information: balancing interests in the use of personal genetic data, 2002, http://www.hgc.gov.uk/insideinformation/ (15 April 2004).
36. Parker M, Lucassen A: Genetic information: a joint account? BMJ 2004; 329: 165-167.
37. ASHG Social Issues Subcommittee on Familial Disclosure: Professional disclosure of familial genetic information. Am J Hum Genet 1998; 474-483.